Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2023-04-21 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
药石科技2022年非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a specialized audit-related statement issued by a certified public accounting firm regarding the 2022 non-operating fund occupation and other related party fund transactions of Nanjing PharmaBlock Technologies, Inc. It references the 2022 audited financial statements and an audit report number, and it includes a detailed summary table of related party transactions. The document is a standalone audit explanation focusing on specific regulatory requirements related to fund occupation and related party transactions, not a full annual report or general audit report. It is not a brief announcement or a certification letter but a detailed audit-related explanatory statement. Therefore, it fits best under the category of Audit Report / Information (AR). The document length (3743 characters) is relatively short but contains substantive audit-related content and tables, not just an announcement or certification. Hence, the classification is AR with high confidence. FY 2022
2023-04-21 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2022 Annual Report" of 南京药石科技股份有限公司 (PharmaBlock Sciences (Nanjing), Inc.) and contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, shareholder information, and a full financial report. It includes audited financial statements, signatures from company officers and auditors, and comprehensive business and financial analysis for the fiscal year 2022. The document length is substantial (15,000 characters), and it is not merely an announcement or a brief summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-04-21 Chinese
独立董事关于第三届董事会第十六次会议相关事项的事先认可函
Board/Management Information Classification · 95% confidence The document is a letter from independent directors providing prior approval for agenda items to be discussed at the company's board meeting, specifically regarding the proposal to reappoint an accounting firm for the 2023 audit. It references company bylaws and regulatory rules but does not contain financial data, audit results, or detailed report content. The document is short (611 characters) and serves as a formal management/board communication about governance matters. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters. It is not an audit report itself, nor an announcement of a report publication, nor a regulatory filing or certification. Therefore, the classification is MANG with high confidence.
2023-04-21 Chinese
关于使用部分暂时闲置募集资金及自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Nanjing Yaoshi Technology Co., Ltd. regarding the use of temporarily idle raised funds and own funds for cash management. It details the approval by the board and supervisory committee, the amount of funds involved, investment purposes, risk control measures, and the need for shareholder approval. The document is a formal announcement about a financing and capital management activity, specifically the use of idle raised funds and own funds for cash management products. It does not contain financial statements or quarterly/yearly financial results, nor is it a report or transcript. It is not a regulatory certification or a voting result announcement. The content fits best under Capital/Financing Update (CAP) as it relates to updates on company fundraising and capital structure usage.
2023-04-21 Chinese
关于公司2023年度对外担保额度预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding its expected external guarantee limit for the year 2023. It includes details about board and supervisory committee meetings, approval of guarantee limits, financial data of the guaranteed subsidiary, and opinions from independent directors and the sponsor institution. The document is an announcement of a corporate governance and financial decision related to guarantees, not a full financial report or audit. It is not a full annual or interim report, nor a call transcript or earnings release. It is also not a proxy solicitation or voting result announcement. The document is regulatory in nature, providing compliance and disclosure information about the guarantee limits and approvals. Given the document length (3436 characters) and content, it is not a report publication announcement but a regulatory filing. Therefore, the best fitting category is Regulatory Filings (RNS).
2023-04-21 Chinese
重大信息内部报告制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '重大信息内部报告制度' (Major Information Internal Reporting System) of 南京药石科技股份有限公司. It outlines procedures, responsibilities, and definitions related to the internal reporting of major information within the company, including legal and regulatory compliance references. It does not contain financial statements, earnings data, or any form of financial results. It is not an announcement or a brief notice but a comprehensive governance-related internal control document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-04-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.